Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.
Why Omnicell stock is drawing attention now Omnicell (OMCL) has recently attracted interest after a sharp move in its share price, with the stock showing gains over the past 3 months and solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback